ATRX mutation possible biomarker for rare neuroendocrine tumours

26 Jan 2015


A somatic mutation in the ATP-dependent helicase (ATRX) gene recently demonstrating potential as a molecular marker for aggressive brain tumours could also serve as a biomarker for rare neuroendocrine tumours, according to research published in Nature Communications. Healio


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story